Citadel Advisors
PLXP

Citadel Advisors’s PLx Pharma Inc. Common Stock PLXP Stock Holding History

Citadel Advisors’s Portfolio PLXP Stock Details PLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-27,600
Closed -$18K – 15748
2022
Q3 		$18K Sell
27,600
-20,300
-42% -$29.9K ﹤0.01% 12123
2022
Q2 		$116K Buy
47,900
+12,700
+36% +$35.3K ﹤0.01% 11268
2022
Q1 		$142K Sell
35,200
-22,200
-39% -$122K ﹤0.01% 11923
2021
Q4 		$460K Sell
57,400
-5,900
-9% -$69.2K ﹤0.01% 9904
2021
Q3 		$1.22M Buy
63,300
+8,500
+16% +$149K ﹤0.01% 7626
2021
Q2 		$756K Buy
54,800
+42,200
+335% +$500K ﹤0.01% 9084
2021
Q1 		$114K Buy
+12,600
New +$92.1K ﹤0.01% 12355

Other funds holding PLXP

PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
SGCA
Steel Grove Capital Advisors Memphis, Tennessee $949M AUM 23.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $50.7M AUM 30.19% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Citadel Advisors's PLXP Position: Q3 2022 in Review

Citadel Advisors sold out of PLx Pharma Inc. Common Stock (PLXP) in Q3 2022, closing a stake of 38,998 shares — an estimated $57.5K sold.

Citadel Advisors first reported a position in PLXP in Q1 2017 and held it in 7 quarters. The position peaked at $1.26M in Q3 2021. 40 funds tracked by Wall St. Rank hold PLXP as of Q3 2022.

  • Citadel Advisors reported no remaining PLx Pharma Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Citadel Advisors sold 38,998 PLx Pharma Inc. Common Stock shares in Q3 2022, an estimated $57.5K.
  • Citadel Advisors first reported a position in PLx Pharma Inc. Common Stock in Q1 2017 and held it in 7 quarters.
  • Citadel Advisors's PLx Pharma Inc. Common Stock position peaked at $1.26M in Q3 2021.
  • 40 funds tracked by Wall St. Rank held PLx Pharma Inc. Common Stock as of Q3 2022.

Based on Citadel Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.